Who holds the patent for Pertuzumab/Trastuzumab/Hyaluronidase?

Introduction to Pertuzumab/Trastuzumab/Hyaluronidase

Overview of the Drug Combination 
The combination of pertuzumab, trastuzumab, and hyaluronidase represents a significant therapeutic advancement in the treatment of HER2-positive breast cancer. Pertuzumab and trastuzumab are both humanized monoclonal antibodies that bind to distinct epitopes on the HER2 receptor, thereby intercepting critical pathways that drive tumor growth and proliferation. The addition of hyaluronidase—a recombinant enzyme—enhances subcutaneous absorption by temporarily degrading hyaluronan in the extracellular matrix, thus allowing for a higher dispersion of the antibodies when delivered via the subcutaneous route. This innovative formulation, marketed under names such as PHESGO, capitalizes on both the complementary mechanisms of dual HER2 blockade and improved patient convenience due to reduced administration times compared to traditional intravenous infusions.

Therapeutic Uses and Benefits 
The therapeutic utility of this combination drug lies primarily in its use to treat patients with HER2-positive breast cancer, in both early-stage and metastatic settings. Combining pertuzumab and trastuzumab has been proven to significantly enhance progression-free survival and response rates while maintaining a tolerable safety profile. The inclusion of hyaluronidase permits subcutaneous administration, leading to benefits such as shorter administration times, reduced need for infusion centers, and improved patient quality of life as patients no longer require lengthy hospital visits. Furthermore, such a formulation is designed to achieve pharmacokinetic profiles that are comparable to intravenous administration, ensuring that the bioavailability and therapeutic efficacy of each component are preserved. Clinical studies and regulatory evaluations have confirmed that the efficacy and overall safety of the combination are maintained, providing an attractive alternative to conventional therapies that typically depend on intravenous delivery.

Patent Information

Patent Holders and Assignees 
The patent portfolio surrounding the combination of pertuzumab, trastuzumab, and hyaluronidase is principally held by Genentech, Inc., which is a constituent of the F. Hoffmann-La Roche Group. In several patent documents, including those focusing on the subcutaneous formulations, the assignee names reflect this connection, with entities such as “F. Hoffmann-La Roche” and "GENENTECH, INC." appearing in the records. For instance, patents related to fixed-dose subcutaneous formulations of pertuzumab alone and combinations of pertuzumab with trastuzumab have been assigned to both Genentech, Inc. and F. Hoffmann-La Roche AG, highlighting their collaborative ownership over the formulation technology. Specifically, reference describes a subcutaneous formulation patent (WO2018136412A2 GENENTECH, INC. and F. HOFFMANN-LA ROCHE AG as current assignees, thereby underscoring their role as primary patent holders for this innovative combination. Similarly, other patent documents such as CN110167594B filings also consistently attribute the product rights to these corporations, cementing their control over the intellectual property landscape associated with the Pertuzumab/Trastuzumab/Hyaluronidase combination.

Patent Details and Claims 
The patents focus on several key aspects that are integral to the formulation and therapeutic use of the combination product: 

Stable and Concentrated Pharmaceutical Formulations: 
A core patent relates to the creation of a highly concentrated, stable pharmaceutical formulation that includes one or more anti-HER2 antibodies, and importantly, incorporates hyaluronidase. The disclosed formulation details the use of buffering agents, stabilizers (such as saccharides, histidine buffers, and nonionic surfactants), and an effective amount of hyaluronidase. The inventors’ strategy was to produce a formulation suitable for subcutaneous injection that would maintain the antibody’s activity while ensuring high purity and stability.

Fixed-Dose Combination and Co-Formulation: 
Patents such as CN110167594B describe fixed-dose subcutaneous formulations specifically designed for ease of use in a clinical setting. These patents claim the precise ratios and pharmaceutical compositions that combine pertuzumab and trastuzumab with hyaluronidase, enabling a consistent product that is safe for patients and can be administered with minimal additional equipment.

Manufacturing Processes and Package Inserts: 
Some patents also extend their claims to include methods of manufacturing the vial or intravenous package containing the combination drug, as well as the inclusion of package inserts that communicate vital safety and efficacy data to health-care providers. These documents ensure that the formulation not only meets regulatory standards but is also packaged in a manner that upholds and communicates its therapeutic advantages.

Pharmaceutical and Legal Boundaries: 
In detailing the composition and method of use, the patents also delineate the industrial applicability and protection strategies surrounding the combination product. This includes ensuring that the patents cover the use of the specific hyaluronidase enzyme from recombinant sources, thereby granting broader protection by linking the biological activity of the enzyme with the antibodies to generate a unique clinical benefit not seen with either component administered separately.

Together, these details articulate a well-rounded patent protection strategy that secures the rights to both the composition and the methods of manufacturing and administering the combination of pertuzumab, trastuzumab, and hyaluronidase.

Commercial and Legal Implications

Market Impact and Competition 
The introduction of a subcutaneous combination formulation has had far-reaching commercial implications in the oncology therapeutics market. By enabling subcutaneous administration, the product offers a more patient-friendly alternative compared to traditional intravenous dosing. The resulting reduced administration time and minimized resource demands for treatment centers not only improve patient satisfaction but also facilitate a significant market expansion by allowing treatment in a broader array of settings. 

Moreover, the strong patent protection held by Genentech, Inc. and F. Hoffmann-La Roche AG creates notable barriers to entry for competitors. The comprehensive nature of the patents—covering formulation composition, manufacturing processes, and specific dosing regimens—has made it challenging for other pharmaceutical companies to develop similar biosimilar products without extensive infringement concerns. This protection is a critical component of the company’s commercial strategy, ensuring that once launched, the combination product retains a dominant market position until its patents begin to expire.

Furthermore, the competitive edge offered by this combination is enhanced by its proven clinical outcomes. The dual HER2 blockade provided by pertuzumab and trastuzumab has revolutionized the treatment paradigm for HER2-positive breast cancer, and when combined with the enhanced bioavailability provided by hyaluronidase, it ensures maximal therapeutic benefit with convenient administration. This scientific and commercial synergy drives its market success and positions the product as a flagship therapy in the oncology space.

Legal Challenges and Considerations 
From a legal standpoint, the robust patent portfolio has not been without its challenges. The complexity of the formulation and the breadth of patent claims have occasionally led to litigation and disputes, as is common when advanced biologics and biosimilar candidates enter the market. For example, references indicate that there have been lawsuits related to patent infringement involving components like pertuzumab or its combinations in various jurisdictions. 

The legal strategies employed by F. Hoffmann-La Roche and Genentech, Inc. are designed to preempt potential infringement by competitors as well as to protect their significant research and development investments. A comprehensive patent strategy encompassing both early patents (covering basic formulations and methods of use) and subsequent enhancements (such as improved stability, patient convenience, and novel manufacturing techniques) has helped to mitigate litigation risks. This layered protection makes it increasingly difficult for biosimilar manufacturers to confidently navigate the legal landscape without risking infringement litigation.

Legally, the combination product’s patents also impact the overall pricing structure within the market. The strong intellectual property protection effectively delays the entry of competing products, which in turn sustains a higher market price for the original product. This interplay between patent protection and market exclusivity is a critical factor influencing pricing strategies and reimbursement negotiations in many countries.

In summary, the legal robustness of the patents not only reinforces market exclusivity for the current product but also deters potential biosimilar entrants, thereby shaping both competitive dynamics and pricing structures in global HER2-targeted oncology therapies.

Future Developments

Upcoming Patent Expirations 
Despite the extensive protection currently enjoyed by the combination product, patents are inherently subject to temporal limitations. As several patents related to the combination pertuzumab, trastuzumab, and hyaluronidase formulation were filed over a decade ago, some of these patents are approaching or will eventually reach their expiration dates in the coming years. The expiration timeline varies by jurisdiction and is influenced by factors such as patent extensions based on regulatory approval processes. For instance, some patents filed in the early 2010s will expire in the early 2030s, which provides a window of continued exclusivity followed by a potential influx of biosimilars post-expiration.

The expiration of these patents is closely monitored by the industry, as it marks a significant turning point for market dynamics. As patent protection wanes on the original formulations, competitors may initiate the development of biosimilar or alternative formulations. This anticipated timeline not only affects competitive strategy but also has implications for pricing, reimbursement, and clinical practice as cost‐effective biosimilars enter the market.

Potential for New Formulations or Combinations 
Looking to the future, the intellectual property landscape remains dynamic. There is considerable scope for innovation in new formulations or combinations that build on the success of the current product. Research continues into improving the stability, concentration, and overall pharmacokinetic profiles of such combination products. For example, subsequent generations of formulations might aim to further minimize injection volumes, enhance patient comfort, or provide an even more rapid onset of therapeutic action.

Another promising area is the exploration of new antibody combinations or adjunct therapies that could be co-formulated with pertuzumab and trastuzumab, perhaps incorporating novel targeting agents or additional supportive excipients. The continuous pursuit of better efficacy and safety profiles means that even after the original patents expire, subsequent patents may cover enhanced formulations or novel dosing regimens. In this respect, companies like F. Hoffmann-La Roche AG and Genentech, Inc. are likely to remain at the forefront of innovation by filing new patents that extend the commercial lifespan of their products or introduce new indications and combinations.

Furthermore, advances in biotechnology and manufacturing processes—such as improvements in recombinant protein production and stabilization techniques—are expected to yield new intellectual property as companies respond to both market needs and competitive pressures. These potential developments underscore the importance of maintaining a robust and evolving patent portfolio that not only protects the current combination product but also anticipates future innovations in HER2-targeted therapy.

Conclusion

In conclusion, the patents for the combination of pertuzumab, trastuzumab, and hyaluronidase are held primarily by Genentech, Inc. and F. Hoffmann-La Roche AG. These entities, operating under the umbrella of the Roche Group, have established a comprehensive and robust patent portfolio that covers the composition, manufacturing methods, and clinical administration of the combination product marketed as PHESGO. The patents provide protection for a formulation that significantly improves patient convenience by enabling subcutaneous administration while maintaining therapeutic efficacy comparable to traditional intravenous routes. 

From a commercial standpoint, this patent strategy has fortified the market position of the combination product by delaying biosimilar competition and justifying the premium pricing often associated with such innovative therapies. Legally, the patents have withstood scrutiny through layered protection strategies that address both early-stage formulation claims and subsequent enhancements, thereby limiting the risk of infringement challenges. However, as some of these patents approach their expiration dates in the coming years, the market is poised for a potential influx of biosimilars and alternative formulations that may drive down costs and increase patient access.

Looking ahead, continued innovation in the field of HER2-targeted therapies is anticipated. Future developments may include new formulations that further enhance drug stability, reduce administration volumes, or combine additional therapeutic agents to address emerging clinical needs. The evolution of the patent landscape will be critical in shaping the competitive dynamics and legal considerations surrounding these products, ensuring that companies can continue to invest in and deliver advanced therapies to patients.

Overall, the patent portfolio held by Genentech and F. Hoffmann-La Roche not only secures current market exclusivity for the pertuzumab/trastuzumab/hyaluronidase combination but also lays the groundwork for innovation that will drive future therapeutic improvements and commercial success. This layered protection strategy—supported by robust patent claims, well-documented manufacturing processes, and a clear demonstration of clinical benefits—ensures that the combination product remains a cornerstone of HER2-positive breast cancer treatment while paving the way for future advancements in oncology therapeutics.

Discover Eureka LS: AI Agents Built for Biopharma Efficiency

Stop wasting time on biopharma busywork. Meet Eureka LS - your AI agent squad for drug discovery.

▶ See how 50+ research teams saved 300+ hours/month

From reducing screening time to simplifying Markush drafting, our AI Agents are ready to deliver immediate value. Explore Eureka LS today and unlock powerful capabilities that help you innovate with confidence.